Varilrix + Stamaril

This entry refers to the use of two distinct, licensed live-attenuated vaccines, **Varilrix** and **Stamaril**, in a clinical research context led by the **University of Surrey**. Varilrix, developed by **GSK**, is a vaccine against the **Varicella-zoster virus** (chickenpox), while Stamaril, developed by **Sanofi**, is a vaccine against the **Yellow Fever virus**. These vaccines were utilized as benchmark immunogens in the **BIOVACSAFE** project, a large-scale European initiative aimed at identifying and validating biomarkers of vaccine reactogenicity and inflammation. In the specific Surrey-led study, healthy adults were immunized with either Varilrix or Stamaril to generate a training dataset of physiological, metabolic, and immune responses to help predict vaccine safety profiles in future development programs.

Brand names

VarilrixStamaril

Other names

Varicella-zoster vaccineYellow Fever vaccineBIOVACSAFE study vaccines